Literature DB >> 28880407

Biomarkers in solid organ transplantation.

Teun van Gelder1,2.   

Abstract

Recipients of solid organs such as the kidney and heart are treated with standard immunosuppressive regimens, and personalized medicine has not yet reached the clinic for this patient population. Biomarkers potentially will allow treatment regimens to be adjusted, according to the needs of the individual patient. Biomarkers may reflect the degree of immunosuppression of the immune system, or they may reflect early damage to the transplanted organ.
© 2017 The British Pharmacological Society.

Entities:  

Keywords:  biomarkers; immunosuppression; rejection; transplantation

Mesh：

Substances：

Year:  2017        PMID： 28880407      PMCID： PMC5698566          DOI： 10.1111/bcp.13391

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  11 in total

1.  Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection.

Authors:  J A Jackson; E J Kim; B Begley; J Cheeseman; T Harden; S D Perez; S Thomas; B Warshaw; A D Kirk
Journal:  Am J Transplant       Date:  2011-08-03       Impact factor: 8.086

Review 2.  Current immunosuppressive treatment after kidney transplantation.

Authors:  Marcia Kho; Karlien Cransberg; Willem Weimar; Teun van Gelder
Journal:  Expert Opin Pharmacother       Date:  2011-02-02       Impact factor: 3.889

3.  Cell-Free DNA and Active Rejection in Kidney Allografts.

Authors:  Roy D Bloom; Jonathan S Bromberg; Emilio D Poggio; Suphamai Bunnapradist; Anthony J Langone; Puneet Sood; Arthur J Matas; Shikha Mehta; Roslyn B Mannon; Asif Sharfuddin; Bernard Fischbach; Mohanram Narayanan; Stanley C Jordan; David Cohen; Matthew R Weir; David Hiller; Preethi Prasad; Robert N Woodward; Marica Grskovic; John J Sninsky; James P Yee; Daniel C Brennan
Journal:  J Am Soc Nephrol       Date:  2017-03-09       Impact factor: 10.121

Review 4.  Aging and the immune response to organ transplantation.

Authors:  Monica M Colvin; Candice A Smith; Stefan G Tullius; Daniel R Goldstein
Journal:  J Clin Invest       Date:  2017-05-15       Impact factor: 14.808

Review 5.  Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation.

Authors:  Mercè Brunet; Maria Shipkova; Teun van Gelder; Eberhard Wieland; Claudia Sommerer; Klemens Budde; Vincent Haufroid; Uwe Christians; Marcos López-Hoyos; Markus J Barten; Stein Bergan; Nicolas Picard; Olga Millán López; Pierre Marquet; Dennis A Hesselink; Ofelia Noceti; Tomasz Pawinski; Pierre Wallemacq; Michael Oellerich
Journal:  Ther Drug Monit       Date:  2016-04       Impact factor: 3.681

6.  Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation.

Authors:  Olga Millán; Klemens Budde; Claudia Sommerer; Irene Aliart; Olesja Rissling; Beatriz Bardaji; Maaren Matz; Martin Zeier; Irene Silva; Lluis Guirado; Mercè Brunet
Journal:  Br J Clin Pharmacol       Date:  2017-09-21       Impact factor: 4.335

7.  The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients.

Authors:  Jiang-Tao Tang; Brenda C de Winter; Dennis A Hesselink; Ferdi Sombogaard; Lan-Lan Wang; Teun van Gelder
Journal:  Br J Clin Pharmacol       Date:  2016-11-30       Impact factor: 4.335

Review 8.  Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation.

Authors:  Klemens Budde; Claudia Sommerer; Olesja Rissling; Maja T Dieterlen; Markus J Barten
Journal:  Ther Drug Monit       Date:  2016-04       Impact factor: 3.681

9.  Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis.

Authors:  S Schaub; P Nickerson; D Rush; M Mayr; C Hess; M Golian; W Stefura; K Hayglass
Journal:  Am J Transplant       Date:  2009-05-13       Impact factor: 8.086

10.  Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells.

Authors:  Petra Glander; Ferdi Sombogaard; Klemens Budde; Teun van Gelder; Pia Hambach; Lutz Liefeldt; Christine Lorkowski; Marco Mai; Hans H Neumayer; Arnold G Vulto; Ron A Mathot
Journal:  Ther Drug Monit       Date:  2009-06       Impact factor: 3.681
View more
  2 in total

Review 1.  The Evolution of Lung Transplant Immunosuppression.

Authors:  Steven Ivulich; Glen Westall; Michael Dooley; Gregory Snell
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 2.  Review: immunosuppression for the lung transplant patient.

Authors:  Sakhee Kotecha; Steven Ivulich; Gregory Snell
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 2.895
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.